Balance Sheet
Cash Flow Statement
Beginning Cash BalanceGains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Net Cash Flow: 2012-2022

Historic Net Cash Flow for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2022 value amounting to $4.8 million.

  • RedHill Biopharma's Net Cash Flow fell 23.03% to $4.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$9.4 million, marking a year-over-year decrease of 3529.09%. This contributed to the annual value of -$961,000 for FY2024, which is 93.32% up from last year.
  • As of Q4 2022, RedHill Biopharma's Net Cash Flow stood at $4.8 million, which was up 140.61% from -$11.8 million recorded in Q3 2022.
  • Over the past 5 years, RedHill Biopharma's Net Cash Flow peaked at $52.5 million during Q1 2020, and registered a low of -$59.4 million during Q2 2020.
  • In the last 3 years, RedHill Biopharma's Net Cash Flow had a median value of $1.2 million in 2020 and averaged -$751,083.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 973.31% in 2020, then plummeted by 821.02% in 2021.
  • RedHill Biopharma's Net Cash Flow (Quarterly) stood at $10.3 million in 2018, then surged by 67.70% to $17.3 million in 2019, then plummeted by 82.19% to $3.1 million in 2020, then spiked by 101.10% to $6.2 million in 2021, then dropped by 23.03% to $4.8 million in 2022.
  • Its Net Cash Flow stands at $4.8 million for Q4 2022, versus -$11.8 million for Q3 2022 and -$1.8 million for Q2 2022.